Of four treatment response measures recorded at 6 months of mepolizumab treatment, an Asthma Control Questionnaire score was ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Other common symptoms can develop ... 2024.07.015 American Academy of Pediatrics. Etiology of eosinophilic esophagitis. Asthma & Allergy Foundation of America. Eosinophilic esophagitis (EoE).

A set of chameleon-like immune cells could be contributing to severe asthma in some patients.Intermediate group 2 i ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

Medically reviewed by Qin Rao, MD Eosinophilic esophagitis (EoE) is a chronic (long-term) condition affecting the esophagus, ...

Eosinophils are a type of immune system cell that typically help your body fight infections. Too many of these cells can cause inflammation in your airways and worsen asthma symptoms. Eos asthma ...

Recent studies have highlighted the role of type 2 inflammation in EOM, which is similar to the inflammatory processes seen in asthma and eosinophilic ... controlling EOM symptoms, but there ...